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A B S T R A C T
Smoking is known to inﬂuence messenger RNA (mRNA) expression in colorectal cancer (CRC) cases. As
microRNAs (miRNAs) are known repressors of mRNAs, we hypothesize that smoking may inﬂuence
miRNA expression, thus altering mRNA expression. Our sample consisted of 1447 CRC cases that had
normal colorectal mucosa and carcinoma miRNA data and lifestyle data. We examined current smoking,
current versus never and former versus never (C/F/N) smoking1, and pack-years smoked with miRNA
expression in normal mucosa as well as differential miRNA expression between paired normal and
carcinoma tissue for colon and rectal tissue to determine associations between smoking and miRNA
expression. We adjusted for multiple comparisons using the Benjamini Hochberg false discovery rate
(FDR).
Signiﬁcant associations were seen for rectal differential miRNA expression only. We analyzed miRNAs
signiﬁcantly associated with smoking with CIMP and MSI status, using a polytomous logistic regression.
Two hundred and thirty-one miRNAs were differentially expressed with current smoking,172 with C/F/N,
and 206 with pack-years smoked; 111 were associated with all three. Forty-three miRNAs were unique to
current smoking, 14 were unique to C/F/N and 57 were unique to pack years smoked. Of the 306 unique
miRNAs associated with cigarette smoking, 41 were inversely associated and 200 were directly associated
with CIMP high or MSI tumor molecular phenotype for either colon or rectal cancer. Our results suggest
that cigarette smoking can alter miRNA expression and, given associations with CIMP high and MSI tumor
molecular phenotype, it is possible that smoking inﬂuences tumor phenotype through altered miRNA
expression.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Long-term and current cigarette smoking has been shown to
increase risk of developing and dying from many cancers, including
colorectal cancer (CRC) [1–3]. We have previously shown that
certain mRNAs are differentially expressed in current smokers as
compared to people who have never smoked [4]. MicroRNAs* Corresponding author.
E-mail addresses: Lila.Mullany@hsc.utah.edu (L.E. Mullany),
Jennifer.Herrick@hsc.utah.edu (J.S. Herrick), Roger.Wolff@hsc.utah.edu
(R.K. Wolff), john.r.stevens@usu.edu (J.R. Stevens), Marty.Slattery@hsc.utah.edu
(M.L. Slattery).
1 C/F/N smoking: Differential miRNA expression in subjects who were current
smokers at time of diagnosis compared to subjects who never smoked, and
differential miRNA expression in former smokers compared to those who had never
smoked.
http://dx.doi.org/10.1016/j.canep.2016.10.011
1877-7821/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article un(miRNAs) are small (22 nucleotides), endogenously expressed,
non-coding RNA molecules that bind to the 30 untranslated region
of the mRNAs to alter mRNA translation into protein [5]. Typically,
miRNAs cause mRNA degradation or block translation [6], however
there is some evidence that in certain environments miRNAs may
facilitate mRNA translation [7]. MiRNAs have been shown to be
differentially expressed in carcinoma tissue as compared to normal
tissue [8–10], and, as miRNAs regulate many different target genes
[6,11], they have been implicated as key effector molecules in the
carcinogenesis process [12]. MiRNAs inﬂuence the translation of
mRNAs, which we have seen are impacted by current cigarette use;
it is possible, then, that smoking alters miRNA expression and
contributes to the previously observed altered mRNA levels.
In this study we evaluate whether current smoking and pack-
years of cigarettes smoked inﬂuence miRNA expression in CRC in
both normal colon and rectal mucosa and differential (paired
carcinoma tissue compared to normal colon and rectal mucosa)der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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levels, with greater or temporal exposure having a larger inﬂuence
on differential expression.
2. Materials and methods
2.1. Study population
Data come from participants in the population-based Diet,
Activity, and Lifestyle study that were recruited from Utah or the
Kaiser Permanente Medical Care Program of Northern California
(KPMCP). Colon cancer cases were identiﬁed as having a primary
adenocarcinoma diagnosed between 1 October 1991 and 30 Sep-
tember 1994, while rectal cancer cases were diagnosed between
May 1997 and May 2001. Eligible cases were between 30 and
79 years of age at diagnosis, currently living in the study area,
spoke English and were able to complete an interview, and had no
prior history of CRC, Crohn’s disease, ulcerative colitis, or known
familial adenomatous polyposis. This study was approved by the
Institutional Review Board at the University of Utah; all
participants signed an informed consent form.
2.2. Smoking data
Data were collected by trained and certiﬁed interviewers using
laptop computers. All interviews were audio-taped as previously
described and reviewed for quality control purposes [13]. The
referent period for the study was two years prior to diagnosis for
cases. As part of the study questionnaire, information was collected
on cigarette smoking history. Anyone who reported having smoked
at least 100 cigarettes in their lifetime was considered to have been
a cigarette smoker. Regular smokers were then deﬁned as anyone
having smoked at least one cigarette a day for six months or longer.
Data also were collected for start and stop dates for smoking in
order to calculate pack-years smoked. We collected data on
number of cigarettes smoked per day, and used amount smoked
along with years smoked to calculate the pack-years. The pack-
years variable was deﬁned as the number of years a subject smoked
a pack or 20 cigarettes a day. For rectal cancer subjects we also
analyzed miRNA expression with exposure to smoke of others in
and outside of the house in non-smokers only.
2.3. MiRNA processing
RNA was extracted from formalin-ﬁxed parafﬁn embedded
tissues and processed as previously described [14]. 100 ng total
RNA was labeled with Cy3 and hybridized to Agilent Human miRNA
Microarrays V19.0 and were scanned on an Agilent SureScan
microarray scanner model G2600D using Agilent Feature Extract
software v.11.5.1.1. Data were required to pass stringent QC
parameters established by Agilent that included tests for excessive
background ﬂuorescence, excessive variation among probe se-
quence replicates on the array, and measures of the total gene
signal on the array to assess low signal. Samples that failed to meet
QC standards were repeated, and if a sample failed QC assessment a
second time the sample was deemed to be of poor quality and was
excluded from down-stream analysis. The Agilent platform was
found to be highly reliable (r = 0.98), and to have reasonable
agreement with NanoString [15] as well as excellent agreement
with qRT-PCR [8]. For unpaired samples due to missing normal
scans, we imputed values whenever possible for normal mucosa as
previously described [16]. In order to minimize differences that
could be attributed to the array, amount of RNA, location on array,
or other factors that could erroneously inﬂuence expression, total
gene signal was normalized by multiplying each sample by a
scaling factor which was the median of the 75th percentiles of allthe samples divided by the 75th percentile of each individual
sample [17]. This scaling factor was implemented using SAS 9.4.
2.4. Statistical analysis
Our sample consisted of 1447 carcinoma tissue and paired
normal colorectal mucosa from subjects for whom smoking data
were available. In this analysis, we included only the miRNAs in
which at least 20% of the samples had some level of detectable
expression in the tissue(s) of interest. We stratiﬁed the data by
tumor site, i.e. colon vs. rectal cancer. The number of miRNAs
analyzed varied from 766 to 817 depending on tissue and tumor
site. We examined four smoking variables (ever smoked, smoking
status (current/former/never), average number of cigarettes
smoked per day, and pack-years smoked for rectal cancer only,
since years starting and stopped was not collected for colon cancer
cases) to determine if there was an association between smoking
cigarettes and miRNA expression. We examined associations in
both normal colon and rectal mucosa and the difference in
expression between paired carcinoma tissue and normal colon and
rectal mucosa. This was done by ﬁtting a linear model to the log
base 2 transformed miRNA expression levels and adjusting for age
at diagnosis, study center and sex. P-values were generated using
the bootstrap method by creating a distribution of 10,000 F
statistics derived by resampling the residuals from the null
hypothesis model of no association between the lifestyle variables
and the miRNAs [18] using the boot package in R. Associations
were considered signiﬁcant if the Benjamini Hochberg (FDR)
adjusted p-values were less than 0.05 [19]. We standardized the
slopes by transforming the miRNAs and continuous smoking
variables to standard normal in order to better compare the results
across the miRNA and cigarette smoking variables.
We analyzed any miRNAs that were signiﬁcantly differentially
expressed between carcinoma and normal mucosa for any
smoking variable with CIMP and MSI tumor molecular phenotype
in rectal and colon cancer subjects. Using a polytomous logistic
regression we assessed associations for CIMP High/MSS, CIMP Low/
MSI, and CIMP High/MSI relative to CIMP Low/MSS. For this
analysis we report odds ratios and 95 percent conﬁdence intervals.
3. Results
The study population consisted of 892 colon cancer cases and
555 rectal cancer cases; approximately 54% of cases were male and
46% were female for colon cases, and 57% of cases were male and
43% were female for rectal cases (Table 1). Approximately 11% of
rectal cases and 14% of colon cases had a family history of CRC.
About 55% of rectal cases and 58% of colon cases had ever smoked,
with approximately 16% of rectal cases and 14% of colon cases
smoking at the time of diagnosis. The average age at diagnosis was
approximately 65 years old for colon subjects and 62 years old for
rectal subjects. The average years smoked was 17.5 for colon cases
and 14.8 for rectal cases; the average pack-years smoked for rectal
cases was 16.1 pack-years.
We saw signiﬁcant ﬁndings for differential miRNA expression,
between carcinoma and normal colonic mucosa tissue, for rectal
cancer only. We saw no signiﬁcant ﬁndings for exposure to smoke
of others in non-smoking rectal cancer cases. After adjustment for
multiple comparisons, 231 miRNAs had signiﬁcantly different
differential expression (carcinoma tissue compared to normal
colon and rectal mucosa) in current smokers as compared to cases
that never smoked or were a former smoker. Thirty-six of these
miRNAs were downregulated with current smoking and 195 were
upregulated. One hundred and seventy-two miRNAs were
associated signiﬁcantly with C/F/N smoking; four of these miRNAs
changed direction from never to former and from never to current,
Table 2
MiRNAs differentially expressed between carcinoma tissue and normal rectal mucosa 
Never & Former Current
Mean miRNA Expression Mean mi
miRNA Carcinoma Tissue Normal Mucosa Carcinom
hsa-miR-1208 26.48 30.79 28.12 
hsa-miR-1224-5p 692.89 820.71 756.13 
hsa-miR-1236-5p 127.80 136.98 140.37 
hsa-miR-1276 2.32 2.00 1.71 
hsa-miR1914-3pb 106.17 121.11 117.74 
hsa-miR-196b-5pb 14.93 2.31 13.55 
hsa-miR-197-5p 2553.58 2891.42 2837.27 
hsa-miR-199b-5p 3.83 0.96 2.70 
hsa-miR-2276 89.25 86.67 96.83 
hsa-miR-3174 12.41 10.63 11.76 
hsa-miR-3187-5p 3.84 2.27 3.10 
hsa-miR-3189-5p 5.19 5.12 4.40 
hsa-miR-320e 34.84 36.31 40.31 
hsa-miR-3676-5p 2912.88 3019.95 3453.19 
hsa-miR-423-3p 15.79 19.47 17.74 
hsa-miR-4257 267.62 316.63 302.40 
hsa-miR-4311 2.99 2.06 2.22 
hsa-miR-4313 22.87 27.84 26.76 
hsa-miR-4322 88.99 88.90 97.53 
hsa-miR4327b 201.55 202.77 223.68 
hsa-miR-4450 4.15 3.17 3.43 
hsa-miR4470b 31.28 37.96 34.27 
hsa-miR-4487 94.43 106.26 101.39 
hsa-miR-4515 280.18 336.05 308.11 
hsa-miR4665-3pb 87.69 110.91 102.16 
hsa-miR4673b 66.94 81.77 74.74 
hsa-miR-4676-5p 2.51 1.80 1.60 
hsa-miR-4695-5p 299.23 347.39 324.06 
hsa-miR-4746-3p 370.75 429.01 409.40 
hsa-miR-5006-5p 544.48 647.79 581.01 
hsa-miR-5189 26.37 28.82 28.72 
hsa-miR-548qb 50.06 69.60 57.11 
hsa-miR-550b2-5pb 26.33 30.43 28.98 
hsa-miR6074b 14.42 14.68 15.16 
hsa-miR-6134 3.12 2.73 2.89 
hsa-miR6165b 299.51 275.50 331.99 
hsa-miR-642a-3p 3129.76 3671.40 3499.61 
hsa-miR-6510-5p 237.90 255.86 271.61 
hsa-miR-6511b-5p 50.18 53.48 55.37 
hsa-miR-652-5p 64.67 72.15 69.38 
hsa-miR-934 5.21 0.70 4.43 
hsa-miR-936 44.86 48.55 48.41 
hsa-miR939-5pb 467.20 552.48 529.55 
a Adjusted for age at diagnosis, study center, and sex.









Age at diagnosis 64.7 (9.5) 61.8 (10.8)
Sex Male 485 (54.4) 316 (56.9)
Female 407 (45.6) 239 (43.1)
Center Kaiser 626 (70.2) 340 (61.3)
Utah 266 (29.8) 215 (38.7)
Family history of colorectal cancer No 770 (86.3) 493 (89.0)
Yes 122 (13.7) 61 (11.0)
Ever Smoked No 373 (41.9) 252 (45.4)
Yes 517 (58.1) 303 (54.6)
Smoking Status Never 373 (41.9) 264 (47.6)
Former 390 (43.8) 200 (36.0)
Current 127 (14.3) 91 (16.4)
Average # of cigarettes/day None 373 (42.0) 264 (47.7)
1–10 142 (16.0) 74 (13.4)
11–20 215 (24.2) 146 (26.4)
>20 159 (17.9) 70 (12.6)
Years smoked 17.5 (18.3) 14.8 (17.8)
Pack-years smoked 16.1 (23.4)
100 L.E. Mullany et al. / Cancer Epidemiology 45 (2016) 98–107while 168 had differential expression increase or decrease in the
same direction progressively from never to former to current. Of
the 168 that had progressive changes in expression, 138 were
upregulated and 30 were downregulated in current versus former
or never smokers. Two hundred and six miRNAs were associated
with pack-years smoked; of these, 37 were downregulated and
169 were upregulated with more pack-years smoked. Forty-three
miRNAs were unique to current smokers (Table 2), 14 were unique
to C/F/N smoking (Table 3), and 57 were unique to pack-years
smoked (Table 4).
One hundred and eleven miRNAs were associated with all three
smoking variables (Table 5). Of these, 110 the same direction of
association for every variable; one miRNA, hsa-miR-432-5p, had a
positive change from never to former but negative changes in
current smoking, never to current smoking, and pack-years
smoked. Of the 110 with the same direction of association, 11 were
downregulated with current smoking, never to former as well as
never to current smoking, and with pack-years smoked; 99 miRNAs
were upregulated with these variables.
Associations between the miRNAs associated with cigarette
smoking the tumor molecular phenotype are summarized inand associated with only current smoking.
RNA Expression P-values
a Tissue Normal Mucosa Betaa Raw FDR
30.02 0.3125 0.0077 0.0328
800.96 0.3061 0.0076 0.0328
134.74 0.2980 0.0084 0.0344
2.20 0.3268 0.0057 0.0280
121.75 0.3159 0.0066 0.0301
2.43 0.2829 0.0135 0.0456
2837.46 0.2992 0.0075 0.0328
1.30 0.3156 0.0053 0.0277
83.14 0.3298 0.0035 0.0230
11.19 0.2838 0.0149 0.0495
2.52 0.3043 0.0072 0.0321
5.45 0.3166 0.0066 0.0301
37.27 0.2885 0.0126 0.0441
3181.99 0.3046 0.0076 0.0328
20.02 0.2829 0.0146 0.0489
318.08 0.3193 0.0053 0.0277
2.21 0.3104 0.0067 0.0304
28.83 0.2910 0.0113 0.0403
88.46 0.2852 0.0130 0.0451
198.38 0.3095 0.0057 0.0280
3.49 0.3095 0.0065 0.0301
37.99 0.2977 0.0098 0.0370
103.66 0.3258 0.0049 0.0263
333.67 0.3322 0.0041 0.0240
113.04 0.3050 0.0094 0.0364
81.75 0.3028 0.0098 0.0370
2.05 0.3245 0.0045 0.0247
341.22 0.2873 0.0131 0.0452
428.00 0.3224 0.0055 0.0280
634.52 0.2835 0.0132 0.0452
28.62 0.2977 0.0091 0.0354
67.71 0.3043 0.0071 0.0320
30.15 0.2897 0.0119 0.0419
14.07 0.3116 0.0085 0.0344
3.19 0.3222 0.0056 0.0280
272.61 0.3083 0.0079 0.0331
3525.75 0.2994 0.0087 0.0344
250.33 0.2993 0.0099 0.0370
53.09 0.2901 0.0141 0.0474
69.04 0.3105 0.0059 0.0285
0.86 0.2899 0.0111 0.0398
48.26 0.3020 0.0075 0.0328
547.50 0.3040 0.0079 0.0331
rvival.
Table 3
MiRNAs differentially expressed between carcinoma tissue and normal rectal mucosa and associated with only C/F/N smoking.
Never Former Current














hsa-miR-141-3p 33.88 22.13 29.52 23.59 0.2704 32.73 24.52 0.2624 0.0084 0.0438
hsa-miR-16-5p 77.93 58.03 67.77 55.89 0.2250 65.75 58.32 0.3325 0.0079 0.0427
hsa-miR17-5pb 58.74 12.85 49.85 13.12 0.1944 47.11 13.85 0.3429 0.0098 0.0461
hsa-miR-200a-3p 25.70 17.69 21.28 18.25 0.3084 23.06 19.24 0.3464 0.0017 0.0271
hsa-miR-21-5p 404.36 117.53 360.56 120.50 0.2770 374.43 128.14 0.3106 0.0049 0.0383
hsa-miR-29a-3pb 103.95 39.54 87.04 39.29 0.2676 90.14 40.54 0.3469 0.0019 0.0271
hsa-miR-29b-3p 20.28 6.72 17.14 7.26 0.3570 17.01 7.09 0.3591 <0.0001 0.0256
hsa-miR-30b-5p 21.97 20.00 18.53 19.26 0.1801 21.11 20.73 0.3485 0.0107 0.0484
hsa-miR-3150b-
5pb
11.39 16.30 12.30 15.89 0.2478 14.18 15.96 0.3330 0.0069 0.0411
hsa-miR-3620-3p 7.04 8.66 7.35 8.06 0.3440 7.52 7.90 0.2400 0.0016 0.0271
hsa-miR425-5pb 11.85 5.52 9.95 5.80 0.3016 10.45 5.92 0.2500 0.0054 0.0394
hsa-miR-4485 1074.42 1298.17 1012.29 1335.83 0.2928 1127.54 1347.92 0.0495 0.0043 0.0362
hsa-miR-509-3-5p 5.58 6.67 5.96 6.40 0.2902 6.00 6.36 0.2117 0.0099 0.0463
hsa-miR6084b 13.00 14.82 14.26 15.10 0.2296 15.58 14.63 0.3358 0.0069 0.0411
aAdjusted for age at diagnosis, study center, and sex.
b These miRNAs have been previously associated with differential expression and survival.
L.E. Mullany et al. / Cancer Epidemiology 45 (2016) 98–107 101Table 6 (Supplemental Table 4 has complete data for rectal cancer
and Supplemental Table 5 has complete data for colon cancer).
Differential expression of 39 miRNAs was directly associated, and
of ﬁve miRNAs was inversely associated, with CIMP Low/MSI
tumors in both colon and rectal cancer subjects (Table 6), however
the magnitude of the associations, although less precise for rectal
cancer, were much stronger. Nine miRNAs in rectal subjects and
11 in colon had differential expression that was inversely
associated with CIMP Low/MSI, while 28 miRNAs in rectal and
79 in colon cancer subjects were differentially expressed in a direct
relationship to CIMP Low/MSI. Few miRNAs associated with
smoking were signiﬁcantly associated with a CIMP High/MSS
tumor. The strongest associations with the most miRNAs
associated with cigarette smoking were observed when the tumor
phenotype was CIMP High/MSI. Current smoking versus never
smoked was signiﬁcantly associated with CIMP High/MSI, OR =
2.42, 95% CI 1.16  5.03. Twelve miRNAs were differentially
expressed in an inverse manner with CIMP High/MSI in both colon
and rectal cancer cases, and 135 were differentially expressed in a
direct manner for both tumor sites. Additionally, ﬁve miRNAs were
inversely associated with CIMP High/MSI rectal tumors and of
54 miRNAs were directly associated with CIMP High/MSI rectal
tumors
4. Discussion
In this study, we investigated whether cigarette smoking
inﬂuences miRNA expression in CRC subjects. Two hundred and
thirty-one miRNAs were associated with current smoking,172 with
C/F/N smoking, and 206 with pack-years smoked. One hundred and
ninety-two miRNAs were associated with two or more smoking
criteria, while 111 were associated with all three variables and
114 were unique to only one. Together, these results suggest that a
lifestyle factor, such as cigarette smoking, is indeed able to alter
endogenous levels of miRNAs in rectal cancer subjects. Addition-
ally, while some miRNAs are altered with smoking in general,
different amounts and type of exposure also results in different
dysregulated miRNAs.
Previously, we identiﬁed miRNAs whose differential expression
between carcinoma tissue and normal colorectal mucosa were
associated signiﬁcantly with survival after being diagnosed with
rectal cancer [20]. In that study, hazard ratios and 95% conﬁdence
intervals were adjusted for age, sex, AJCC stage, and MSI tumorstatus. Of the 43 miRNAs associated with only current smoking,
differential expression of 11 miRNAs had previously been
identiﬁed with altered survival after diagnosis with rectal cancer.
One of these miRNAs (hsa-miR-196b-5p) had improved survival in
rectal cases when this miRNA was upregulated in rectal carcinoma
tissue relative to normal mucosa, and this miRNA had decreased
differential (carcinoma minus normal mucosa) expression in
current smokers. Ten miRNAs (hsa-miR-1914-3p, hsa-miR-4327,
hsa-miR-4470, hsa-miR-4665-3p, hsa-miR-4673, hsa-miR-548q,
hsa-miR-550b-2-5p, hsa-miR-6074, hsa-miR-6165, and hsa-miR-
939-5p) were upregulated in tumors of rectal cases of current
smokers and the differential expression of these miRNAs was
previously shown to be associated with worse survival when
expression in carcinoma tissue increased. Five of the 14 miRNAs
associated signiﬁcantly with only C/F/N smoking were previously
identiﬁed as being differentially expressed between carcinoma and
normal mucosa and this change in expression was also shown to
alter survival of rectal cancer cases. Three of these miRNAs (hsa-
miR-17-5p, hsa-miR-29a-3p, and hsa-miR-425-5p) improved
survival, and were downregulated in tumors of current and former
smokers compared to those who never smoked. Two of the miRNAs
(hsa-miR-3150b-5p and hsa-miR-6084) increased risk of death
from colorectal cancer in cases diagnosed with rectal cancer when
expression increased in carcinoma tissue; both miRNAs had higher
expression in carcinoma tissue in both former and current smokers
compared to carcinoma tissue of cases who never smoked. Twelve
of the ﬁfty-seven of the miRNAs associated with only pack-years
smoked were associated with differential expression between
carcinoma and normal mucosa and with colorectal cancer survival
in cases diagnosed with rectal cancer. Four of these miRNAs (hsa-
miR-196a-5p, hsa-miR-429, hsa-miR-508-5p, and hsa-miR-93-5p)
reduced the risk of death from colorectal cancer after being
diagnosed with rectal cancer when expression increased in
carcinoma tissue, and all but one of these (hsa-miR-508-5p) was
downregulated in tumors in cases who smoked more pack-years.
Eight of the miRNAs (hsa-miR-139-3p, hsa-miR-3667-5p, hsa-miR-
425-3p, hsa-miR-4298, hsa-miR-4429, hsa-miR-4481, hsa-miR-
4685-5p, and hsa-miR-4783-3p) increased risk of colorectal cancer
death among rectal cancer cases with expression increases in
carcinoma tissue, and these miRNAs had higher expression in
carcinoma tissue with subjects who smoked more pack-years. Of
the 111 miRNAs associated with all three smoking variables,
69 were previously identiﬁed as being associated with rectal
Table 4
MiRNAs differentially expressed between carcinoma tissue and normal rectal mucosa and associated with only pack-years smoked.
Mean miRNA Expression P-values
miRNA Carcinoma Tissue Normal Mucosa Betaa Raw FDR
hsa-miR-1273g-5p 8.35 8.60 0.0418 0.0130 0.0491
hsa-miR-127-3p 2.27 0.85 0.0744 0.0080 0.0386
hsa-miR-1290 147.04 117.28 0.0578 0.0029 0.0269
hsa-miR139-3pb 7.94 10.64 0.1110 0.0124 0.0475
hsa-miR-146b-5p 3.35 1.27 0.1280 0.0041 0.0299
hsa-miR-192-3p 1.98 2.54 0.1243 0.0054 0.0351
hsa-miR-196a-5pb 6.29 2.68 0.1548 0.0004 0.0240
hsa-miR-203a 12.40 3.42 0.1715 0.0002 0.0240
hsa-miR-2277-3p 3.99 4.62 0.0277 0.0004 0.0240
hsa-miR-28-5p 1.36 1.69 0.0737 0.0061 0.0363
hsa-miR-3147 31.02 29.77 0.1183 0.0082 0.0388
hsa-miR-320b 76.00 75.48 0.0998 0.0087 0.0397
hsa-miR-320d 41.27 41.01 0.0944 0.0090 0.0406
hsa-miR-330-3p 3.27 5.68 0.1205 0.0060 0.0359
hsa-miR-339-3p 3.41 3.16 0.1126 0.0103 0.0429
hsa-miR-3648 302.77 265.50 0.1188 0.0073 0.0381
hsa-miR3667-5pb 19.58 22.73 0.1104 0.0133 0.0495
hsa-miR-3677-3p 4.49 2.39 0.1125 0.0116 0.0463
hsa-miR-3911 84.61 75.53 0.1290 0.0034 0.0269
hsa-miR-3934-5p 41.73 42.63 0.1307 0.0033 0.0269
hsa-miR425-3pb 12.37 15.09 0.0846 0.0090 0.0406
hsa-miR-4259 17.67 15.88 0.0795 0.0036 0.0273
hsa-miR429b 11.43 5.11 0.1131 0.0098 0.0425
hsa-miR4298b 164.14 149.05 0.1330 0.0036 0.0273
hsa-miR-4419a 62.35 59.78 0.1238 0.0049 0.0342
hsa-miR-4419b 23.99 25.29 0.1165 0.0074 0.0381
hsa-miR-4421 1.62 1.90 0.1106 0.0122 0.0475
hsa-miR4429b 21.85 22.49 0.1257 0.0048 0.0341
hsa-miR-4436b-3p 7.98 6.42 0.1067 0.0126 0.0478
hsa-miR4481b 64.90 69.70 0.1377 0.0022 0.0266
hsa-miR-4513 25.75 25.91 0.1300 0.0034 0.0269
hsa-miR-4640-5p 27.75 25.32 0.1151 0.0097 0.0425
hsa-miR-4667-5p 56.42 56.33 0.1110 0.0106 0.0437
hsa-miR4685-5pb 19.37 20.14 0.1089 0.0124 0.0475
hsa-miR-4698 33.40 34.05 0.1324 0.0031 0.0269
hsa-miR-4710 36.12 34.94 0.1188 0.0074 0.0381
hsa-miR-4743-5p 54.09 53.32 0.1098 0.0126 0.0478
hsa-miR-4758-5p 106.67 105.94 0.1197 0.0075 0.0381
hsa-miR-4778-5p 68.39 52.84 0.1307 0.0034 0.0269
hsa-miR4783-3pb 11.39 13.57 0.1374 0.0024 0.0266
hsa-miR-4800-5p 181.69 154.52 0.1448 0.0014 0.0240
hsa-miR-483-5p 102.04 92.12 0.1398 0.0017 0.0246
hsa-miR-487b 1.78 2.05 0.1290 0.0031 0.0269
hsa-miR508-5pb 2.99 3.42 0.0278 0.0062 0.0363
hsa-miR-514b-5p 29.50 28.13 0.1212 0.0060 0.0359
hsa-miR-5187-5p 1.95 2.19 0.1196 0.0074 0.0381
hsa-miR-5190 26.14 26.81 0.1147 0.0087 0.0397
hsa-miR-532-3p 2.56 1.34 0.1185 0.0079 0.0386
hsa-miR-5585-3p 308.27 307.70 0.1290 0.0046 0.0333
hsa-miR-5585-5p 5.18 5.83 0.1261 0.0051 0.0343
hsa-miR-616-3p 1.22 0.77 0.0628 0.0021 0.0266
hsa-miR-659-5p 1.73 2.59 0.1311 0.0031 0.0269
hsa-miR-6716-3p 4.90 4.75 0.0409 0.0053 0.0350
hsa-miR-6716-5p 3.80 3.73 0.0838 0.0009 0.0240
hsa-miR-758-5p 27.84 29.46 0.0508 0.0103 0.0429
hsa-miR-766-3p 22.63 27.90 0.0713 0.0070 0.0381
hsa-miR93-5pb 35.97 12.16 0.0681 0.0076 0.0383
a Adjusted for age at diagnosis, study center, and sex.
b These miRNAs have been previously associated with differential expression and survival.
102 L.E. Mullany et al. / Cancer Epidemiology 45 (2016) 98–107survival. Four miRNAs (hsa-miR-106b-5p, hsa-miR-19b-3p, hsa-
miR-20b-5p, and hsa-miR-432-5p) were seen to improve survival
and these were generally downregulated in all smoking variables.
Of the 69 previously associated with CRC survival in cases
diagnosed with rectal cancer, 65 were seen to worsen survival
and these were upregulated with every smoking variable. These
data suggest that smoking alters miRNA levels in a manner
conducive to poorer outcomes.
Current smoking was associated with the largest number of
dysregulated miRNAs, with 231 miRNAs whose differentialexpression was signiﬁcantly associated with current versus not
current smoking; pack-years smoked was associated signiﬁcantly
with 206 miRNAs, and had the highest number of unique miRNAs
that were differentially expressed (N = 57). These data show that,
not only are many miRNAs generally dysregulated with any
smoking, there are speciﬁc miRNAs that represent current as well
as amount and duration (embodied by pack-years smoked) of
smoking. Additionally, differential expression of these unique
miRNAs has been shown to be associated signiﬁcantly with altered
survival in rectal cancer subjects. These data support the
Table 5
MiRNAs associated with current smoking, C/F/N smoking and pack-years smoked.
Betaa
miRNA Current Smoking Never vs. Former Never vs. Current Pack-Years
hsa-miR-106b-5pb 0.3240 0.2585 0.4337 0.1597
hsa-miR-1185-1-3p 0.3492 0.0624 0.3756 0.1237
hsa-miR-1185-2-3p 0.3925 0.0841 0.4282 0.1450
hsa-miR-12021 0.4067 0.0485 0.4273 0.1481
hsa-miR1207-5pb 0.3785 0.1107 0.4255 0.1361
hsa-miR1225-5pb 0.3685 0.0829 0.4037 0.1424
hsa-miR1226-5pb 0.3854 0.1882 0.4652 0.1525
hsa-miR1227-5pb 0.3413 0.1035 0.3852 0.1160
hsa-miR-1229-3p 0.4794 0.1478 0.5421 0.1095
hsa-miR1229-5pb 0.3419 0.1298 0.3970 0.1410
hsa-miR1234-5pb 0.3967 0.0929 0.4361 0.1395
hsa-miR-125a-3p 0.3628 0.1325 0.4191 0.1470
hsa-miR-130b-3p 0.3470 0.1079 0.3928 0.1344
hsa-miR134b 0.3889 0.1307 0.4444 0.1423
hsa-miR-138-2-3p 0.3258 0.1233 0.3782 0.1187
hsa-miR-1469 0.3908 0.1560 0.4570 0.1196
hsa-miR149-3pb 0.3351 0.1743 0.4090 0.1181
hsa-miR150-3pb 0.3640 0.0670 0.3924 0.1352
hsa-miR-1587 0.3449 0.0882 0.3823 0.1173
hsa-miR-188-5p 0.3828 0.2098 0.4718 0.1620
hsa-miR-19b-3pb 0.2856 0.2561 0.3942 0.1222
hsa-miR-20b-5pb 0.3292 0.2362 0.4294 0.1305
hsa-miR-3121-3p 0.3705 0.0328 0.3844 0.1219
hsa-miR3138b 0.2932 0.1901 0.3738 0.1380
hsa-miR-3162-5p 0.3507 0.1443 0.4119 0.1340
hsa-miR3185b 0.3578 0.1743 0.4318 0.1343
hsa-miR3187-3pb 0.3029 0.1543 0.3683 0.1225
hsa-miR3188b 0.3751 0.1140 0.4235 0.1320
hsa-miR-33b-3pb 0.3843 0.1037 0.4283 0.1408
hsa-miR345-3pb 0.3234 0.1109 0.3705 0.1488
hsa-miR3621b 0.2991 0.1617 0.3678 0.1051
hsa-miR-3651 0.2860 0.2557 0.3945 0.1114
hsa-miR-3656 0.3801 0.1196 0.4309 0.1216
hsa-miR3663-3pb 0.4170 0.1177 0.4670 0.1433
hsa-miR3665b 0.3961 0.1056 0.4409 0.1316
hsa-miR3679-5pb 0.3396 0.0987 0.3815 0.1300
hsa-miR-373-5p 0.3683 0.0888 0.4060 0.1120
hsa-miR3937b 0.3675 0.1251 0.4205 0.1290
hsa-miR3940-5pb 0.3637 0.0924 0.4029 0.1223
hsa-miR3945b 0.3190 0.1568 0.3855 0.1159
hsa-miR3960b 0.3710 0.1280 0.4254 0.1444
hsa-miR4270b 0.4566 0.1074 0.5022 0.1746
hsa-miR-4271 0.3615 0.1231 0.4138 0.1388
hsa-miR4281b 0.4036 0.0565 0.4275 0.1452
hsa-miR-4304 0.3229 0.1970 0.4065 0.1571
hsa-miR432-5pb 0.3634 0.1652 0.2933 0.0580
hsa-miR4433-3pb 0.3621 0.1150 0.4109 0.1420
hsa-miR-4442 0.3462 0.0744 0.3777 0.1404
hsa-miR4443b 0.3592 0.0282 0.3711 0.1311
hsa-miR4459b 0.3270 0.1111 0.3741 0.1133
hsa-miR4463b 0.3475 0.0852 0.3836 0.1497
hsa-miR4466b 0.4036 0.1375 0.4619 0.1422
hsa-miR-4476 0.3621 0.1176 0.4121 0.1313
hsa-miR-4484 0.3822 0.0646 0.4096 0.1357
hsa-miR-4496 0.3775 0.1499 0.4411 0.1602
hsa-miR4499b 0.3372 0.1257 0.3905 0.1393
hsa-miR4508b 0.3430 0.1441 0.4041 0.1302
hsa-miR4516b 0.4308 0.1052 0.4754 0.1434
hsa-miR-4530 0.3611 0.0590 0.3861 0.1180
hsa-miR4534b 0.3288 0.1076 0.3744 0.1416
hsa-miR-4535 0.3563 0.1111 0.4035 0.1234
hsa-miR-4538 0.3610 0.0744 0.3926 0.1160
hsa-miR-4539 0.5240 0.2030 0.6101 0.1816
hsa-miR4634b 0.3583 0.1556 0.4243 0.1526
hsa-miR-4646-5p 0.3163 0.1306 0.3717 0.1245
hsa-miR-4651 0.3795 0.1688 0.4511 0.1427
hsa-miR4655-5pb 0.3497 0.0956 0.3902 0.1173
hsa-miR4664-3pb 0.3634 0.1665 0.4340 0.1137
hsa-miR4665-5pb 0.3253 0.2652 0.4378 0.1404
hsa-miR-4669 0.3472 0.1225 0.3992 0.1116
hsa-miR4687-3pb 0.3893 0.0693 0.4187 0.1363
hsa-miR4690-5pb 0.3449 0.0919 0.3839 0.1307
hsa-miR-4700-5p 0.3031 0.1716 0.3759 0.1163
hsa-miR-4701-3p 0.2990 0.1822 0.3763 0.1418
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Table 5 (Continued)
Betaa
miRNA Current Smoking Never vs. Former Never vs. Current Pack-Years
hsa-miR4734b 0.3823 0.1301 0.4376 0.1230
hsa-miR4739b 0.3876 0.0814 0.4221 0.1334
hsa-miR-4740-5p 0.3805 0.1893 0.4608 0.1324
hsa-miR4741b 0.3299 0.1453 0.3916 0.1415
hsa-miR-4745-5p 0.3852 0.1719 0.4582 0.1319
hsa-miR-4763-3p 0.3866 0.0937 0.4263 0.1292
hsa-miR-4767 0.3502 0.1117 0.3975 0.1141
hsa-miR-4787-3p 0.3618 0.1469 0.4241 0.1119
hsa-miR4787-5pb 0.3331 0.1020 0.3764 0.1146
hsa-miR-484 0.3872 0.0332 0.4013 0.1189
hsa-miR498b 0.3321 0.1042 0.3763 0.1183
hsa-miR5001-5pb 0.3668 0.0957 0.4074 0.1214
hsa-miR-500a-3p 0.3082 0.1597 0.3760 0.1226
hsa-miR5195-3pb 0.3657 0.0876 0.4029 0.1438
hsa-miR-550a3-5pb 0.3391 0.0485 0.3597 0.1250
hsa-miR-557 0.3773 0.1589 0.4447 0.1435
hsa-miR572b 0.3640 0.0900 0.4022 0.1293
hsa-miR-5787 0.2933 0.1829 0.3709 0.1195
hsa-miR601b 0.3915 0.1433 0.4523 0.1451
hsa-miR6068b 0.3695 0.1019 0.4128 0.1225
hsa-miR-6076 0.3567 0.0598 0.3821 0.1212
hsa-miR6086b 0.3344 0.1146 0.3831 0.1256
hsa-miR6087b 0.4023 0.0505 0.4238 0.1354
hsa-miR6088b 0.3818 0.0590 0.4068 0.1370
hsa-miR6089b 0.3912 0.1205 0.4423 0.1331
hsa-miR6090b 0.4363 0.1023 0.4797 0.1529
hsa-miR6124b 0.3394 0.0816 0.3740 0.1457
hsa-miR6125b 0.3672 0.1027 0.4107 0.1214
hsa-miR6126b 0.3887 0.1204 0.4398 0.1268
hsa-miR-617 0.3833 0.1717 0.4562 0.1249
hsa-miR638b 0.3835 0.1030 0.4272 0.1300
hsa-miR6722-3pb 0.3570 0.1116 0.4044 0.1481
hsa-miR-6723-5p 0.3597 0.0792 0.3933 0.1418
hsa-miR6724-5pb 0.3419 0.0944 0.3820 0.1313
hsa-miR-770-5p 0.3457 0.0423 0.3637 0.1213
hsa-miR877-5pb 0.3441 0.1394 0.4032 0.1504
hsa-miR887b 0.3314 0.1118 0.3788 0.1162
a Adjusted for age at diagnosis, study center, and sex.
b These miRNAs have been previously associated with differential expression and survival.
104 L.E. Mullany et al. / Cancer Epidemiology 45 (2016) 98–107hypothesis that current smoking does indeed inﬂuence a larger
number of miRNAs, however it also supports the notion that
cigarette smoking in a large amount, regardless of contemporari-
ness to diagnosis, is able to inﬂuence miRNA expression in a unique
manner and possibly alter survival of rectal cancer in a negative
manner.
Previously, we identiﬁed mRNAs that were differentially
expressed in colon tissue of current smokers versus people who
never smoked [4]. In order to see if miRNAs associated with
smoking could be inﬂuencing mRNA expression, we found the
target genes for the ﬁve miRNAs that were unique to C/F/N
smoking whose differential expression was previously seen to be
associated with rectal cancer survival, as these miRNAs are more
likely to be inﬂuencing mRNA expression. Three mRNAs from this
list were previously shown to be dysregulated in current smokers:
FGA (fold change = 28.01), RBM20 (fold change = 2.99), and YY2 (fold
change = 3.34) were all upregulated in current smokers [4]. Hsa-
miR-17-5p is known to regulate RBM20 and hsa-miR-29a-3p is
known to regulate FGA and YY2; both of these miRNAs have
decreasing expression in carcinoma tissue and increasing expres-
sion in normal colonic mucosa in current smokers compared to
people who never smoked (BetaCvs.N = 0.3429 for hsa-miR-17-5p;
BetaCvs.N = 0.3469 for hsa-miR-29a-3p). This could explain the
increased expression of these target genes. Our past study on
mRNA used differential expression in colon tissue. However, the
miRNAs that are differentially expressed in regards to smoking are
differentially expressed in rectal tissue. This may account forincomplete overlapping between target genes of miRNA and our
previous report of smoking and mRNA expression. It is likely that
multiple miRNAs regulate these target genes, and while the
observed miRNA-mRNA expression direction is in concordance
with the hypothesis that the altered miRNA expression contributes
to the mRNA differential expression, it is not the only possible
interaction.
We analyzed all miRNAs signiﬁcantly differentially expressed
across any of the smoking variables for associations with CIMP and
MSI tumor phenotype in both colon and rectal tissues. We have
previously shown that cigarette smoking is more likely to be
associated with MSI and CIMP High tumors in colon cancer cases
[21–23]. Overall, of the 306 miRNAs associated with cigarette
smoking, 41 were inversely associated with either CIMP High or
MSI tumor phenotype and 200 were directly associated with CIMP
High or MSI tumor molecular phenotype for either colon or rectal
cancer, with directionality consistent across tissue types. Associ-
ations with these miRNAs were generally stronger for rectal
tumors, however given the few MSI rectal cases, the estimates
were much less precise than those observed for colon cancer. These
results suggest that smoking may alter miRNAs, whose differential
expression may inﬂuence CIMP and MSI tumor phenotype.
Ten miRNAs were differentially expressed in rectal tissue across
current smokers versus those who had never smoked as well as
with CIMP High/MSI tumor phenotype. Five of these, hsa-miR-29a-
3p, hsa-miR-29b-3p, hsa-miR-30b-5p, hsa-miR-3150b-5p, and
hsa-miR-425-5p, were associated with both current versus never
Table 6
MicroRNAs that are signiﬁcantly differentially expressed with cigarette smoking and are associated with CIMP and/or MSI status in colon and rectal cancer subjects with an FDR<0.05.
CIMP Low/MSI CIMP High/MSS CIMP High/MSI




hsa-miR-320c, hsa-miR-1207-5p, hsa-miR-1225-5p, hsa-miR-1229-3p,
hsa-miR-1234-5p, hsa-miR-125a-3p, hsa-miR-134, hsa-miR-135a-3p, hsa-
miR-188-5p, hsa-miR-1914-3p, hsa-miR-3610, hsa-miR-3917, hsa-miR-
3945, hsa-miR-3960, hsa-miR-4270, hsa-miR-4459, hsa-miR-4470, hsa-
miR-4499, hsa-miR-4508, hsa-miR-4516, hsa-miR-4530, hsa-miR-4532,
hsa-miR-4673, hsa-miR-4739, hsa-miR-4745-5p, hsa-miR-5006-5p, hsa-
miR-5088, hsa-miR-520b, hsa-miR-575, hsa-miR-5787, hsa-miR-6086,
hsa-miR-6090, hsa-miR-6126, hsa-miR-617, hsa-miR-718, hsa-miR-762,
hsa-miR-1469, hsa-miR-3676-5p, hsa-miR-877-5p
hsa-miR-3622a-5p hsa-miR-1202, hsa-miR-1226-5p, hsa-miR-1307-5p, hsa-miR-149-3p, hsa-
miR-150-3p, hsa-miR-3150b-5p, hsa-miR-3646, hsa-miR-3652, hsa-miR-
3666, hsa-miR-3667-5p, hsa-miR-371a-5p, hsa-miR-423-3p, hsa-miR-
4253, hsa-miR-4463, hsa-miR-4476, hsa-miR-4515, hsa-miR-4655-5p,
hsa-miR-4664-3p, hsa-miR-4665-3p, hsa-miR-4665-5p, hsa-miR-4783-
3p, hsa-miR-4787-3p, hsa-miR-550b-2-5p, hsa-miR-601, hsa-miR-623,
hsa-miR-6723-5p, hsa-miR-6724-5p, hsa-miR-887, hsa-miR-940, hsa-
miR-99b-3p, hsa-miR-5189, hsa-miR-1185-1-3p, hsa-miR-1185-2-3p, hsa-
miR-1207-5p, hsa-miR-1225-5p, hsa-miR-1227-5p, hsa-miR-1229-3p,
hsa-miR-1229-5p, hsa-miR-1233-1-5p, hsa-miR-1234-5p, hsa-miR-125a-
3p, hsa-miR-1275, hsa-miR-129-5p, hsa-miR-134, hsa-miR-135a-3p, hsa-
miR-1587, hsa-miR-188-5p, hsa-miR-1914-3p, hsa-miR-1915-3p, hsa-miR-
197-5p, hsa-miR-2861, hsa-miR-3162-5p, hsa-miR-3187-3p, hsa-miR-
3188, hsa-miR-3610, hsa-miR-3620-5p, hsa-miR-3665, hsa-miR-3679-5p,
hsa-miR-3917, hsa-miR-3937, hsa-miR-3940-5p, hsa-miR-3945, hsa-miR-
4257, hsa-miR-4270, hsa-miR-4271, hsa-miR-4281, hsa-miR-4419b, hsa-
miR-4429, hsa-miR-4459, hsa-miR-4466, hsa-miR-4470, hsa-miR-4499,
hsa-miR-4505, hsa-miR-4507, hsa-miR-4508, hsa-miR-4516, hsa-miR-
4530, hsa-miR-4532, hsa-miR-4535, hsa-miR-4538, hsa-miR-4651, hsa-
miR-4669, hsa-miR-4672, hsa-miR-4673, hsa-miR-4687-3p, hsa-miR-
4690-5p, hsa-miR-4721, hsa-miR-4739, hsa-miR-4740-5p, hsa-miR-4745-
5p, hsa-miR-4746-3p, hsa-miR-4763-3p, hsa-miR-4787-5p, hsa-miR-
5001-5p, hsa-miR-5006-5p, hsa-miR-5088, hsa-miR-5195-3p, hsa-miR-
520b, hsa-miR-548q, hsa-miR-557, hsa-miR-572, hsa-miR-575, hsa-miR-
5787, hsa-miR-6068, hsa-miR-6076, hsa-miR-6084, hsa-miR-6086, hsa-
miR-6087, hsa-miR-6088, hsa-miR-6089, hsa-miR-6090, hsa-miR-6125,
hsa-miR-6126, hsa-miR-6127, hsa-miR-617, hsa-miR-638, hsa-miR-671-
5p, hsa-miR-6722-3p, hsa-miR-718, hsa-miR-762, hsa-miR-874, hsa-miR-
937-5p, hsa-miR-939-5p, hsa-miR-1208, hsa-miR-1224-5p, hsa-miR-1469,
hsa-miR-3621, hsa-miR-3622a-5p, hsa-miR-373-5p, hsa-miR-4486, hsa-





hsa-miR-196a-5p, hsa-miR-196b-5p, hsa-miR-20b-5p, hsa-miR-215, hsa-
miR-30b-5p
hsa-miR-196b-5p hsa-miR-196b-5p, hsa-miR-127-3p, hsa-miR-19b-3p, hsa-miR-20a-5p,
hsa-miR-20b-5p, hsa-miR-215, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-





hsa-miR-3663-3p, hsa-miR-4534, hsa-miR-4634, hsa-miR-1202, hsa-miR-
1225-3p, hsa-miR-1226-5p, hsa-miR-1307-5p, hsa-miR-139-3p, hsa-miR-
3150b-5p, hsa-miR-345-5p, hsa-miR-3646, hsa-miR-3652, hsa-miR-3667-
5p, hsa-miR-4253, hsa-miR-4476, hsa-miR-4664-3p, hsa-miR-4665-3p,
hsa-miR-4689, hsa-miR-4767, hsa-miR-4783-3p, hsa-miR-5190, hsa-miR-
601, hsa-miR-6085, hsa-miR-6510-5p, hsa-miR-6723-5p, hsa-miR-877-3p,
hsa-miR-887, hsa-miR-940
hsa-miR-4721, hsa-miR-4470 hsa-miR-1183, hsa-miR-1236-5p, hsa-miR-1249, hsa-miR-2392, hsa-miR-
3138, hsa-miR-3156-5p, hsa-miR-3158-5p, hsa-miR-3185, hsa-miR-3194-
5p, hsa-miR-320a, hsa-miR-320b, hsa-miR-33b-3p, hsa-miR-345-3p, hsa-
miR-3648, hsa-miR-3656, hsa-miR-3934-5p, hsa-miR-423-5p, hsa-miR-
4259, hsa-miR-4304, hsa-miR-4322, hsa-miR-4327, hsa-miR-4417, hsa-
miR-4433-3p, hsa-miR-4433-5p, hsa-miR-4442, hsa-miR-4484, hsa-miR-
4487, hsa-miR-4488, hsa-miR-4646-5p, hsa-miR-4685-5p, hsa-miR-4707-
5p, hsa-miR-4726-5p, hsa-miR-4741, hsa-miR-4743-5p, hsa-miR-4758-5p,
hsa-miR-4788, hsa-miR-4793-5p, hsa-miR-498, hsa-miR-5196-5p, hsa-
miR-550a-3-5p, hsa-miR-602, hsa-miR-642b-3p, hsa-miR-6511b-5p, hsa-
miR-652-5p, hsa-miR-936, hsa-miR-1225-3p, hsa-miR-139-3p, hsa-miR-





hsa-miR-106b-5p, hsa-miR-140-3p, hsa-miR-425-5p, hsa-miR-501-3p,
hsa-miR-126-3p, hsa-miR-200a-3p, hsa-miR-203a, hsa-miR-429, hsa-
miR-4709-3p





































































































































































































































































































































































































































































































































































































































































































































































































































106 L.E. Mullany et al. / Cancer Epidemiology 45 (2016) 98–107smoking as well as CIMP High/MSI phenotype for both rectal and
colon differential tissue, while hsa-miR-17-5p, hsa-miR-200a-3p,
hsa-miR-4485 were associated only in colon tissue, and hsa-miR-
141-3p and hsa-miR-6084 were associated only in rectal tissue.
Seven of ten miRNAs, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-
30b-5p, hsa-miR-425-5p, hsa-miR-17-5p, hsa-miR-200a-3p, and
hsa-miR-141-3p had decreased differential expression in current
smokers as compared to never smokers, and this differential
expression was indirectly associated with CIMP High/MSI status.
Two miRNAs, hsa-miR-3150b-5p and hsa-miR-6084, had increased
differential expression in current smokers compared to never
smokers, and this increase in expression was directly associated
with CIMP High/MSI. One miRNA, hsa-miR-4485, had increased
differential expressed in current smokers with colon cancer, and
this was indirectly associated with CIMP High/MSI. Current
smoking compared to never smoked showed a signiﬁcant
association with CIMP High/MSI tumor phenotype in colon cancer
cases, OR = 2.42, 95% CI 1.16–5.03. As nine of the 10 miRNAs
associated with both current versus never smoking and CIMP High/
MSI tumor phenotype had agreement in the direction of their
associations, i.e. increased differential expression with current
versus never smoking as well as a direct relationship with CIMP
High/MSI or decreased differential expression and an inverse
relationship, our data suggests that current versus never smoking
alters miRNA expression, and this alteration inﬂuences the
development of a CIMP High/MSI tumor.
The study has several strengths including our large sample size.
This enabled us to look at colon and rectal samples separately.
Since we only found miRNAs signiﬁcantly differentially expressed
with smoking among rectal cancer cases, we may not have found
signiﬁcant results if we had combined colon and rectal cancers or
examined only colon cancer cases. We also consider our platform
as an asset in this study. As previously stated, our platform has very
high reliability and good concordance with other methods [8,15].
The large microarray platform enables a discovery approach, which
is needed since previous studies have not examined miRNA
expression and cigarette smoking in colorectal tissue. Another
strength is the range of data available for these analyses. These data
enabled us to investigate a variety of smoking variables, which was
essential to this study, as we have shown that smoking temporality,
duration, and amount have different inﬂuences on miRNA
expression. Additionally, we have been able to examine not only
how smoking is associated with miRNA expression but also how
miRNAs associated with cigarette smoking are also associated with
tumor molecular phenotypes that have been associated with
cigarette smoking.
A limitation in this study is that, given the large numbers of
miRNAs, and the overlap in genes targeted by the different miRNAs,
it is very difﬁcult to discern distinct biological pathways altered by
speciﬁc miRNAs associated with smoking. This limitation is not
unique to our study, but a limitation of the ﬁeld in general. Since
each miRNA can regulate thousands of genes, it is unknown which
of the many pathways and genes targeted are most important for
colorectal cancer. Additionally, most miRNA-functionality tools
available are not tissue speciﬁc, and this is likely a detriment to
performing functional analysis based on miRNAs only identiﬁed as
being associated with cigarette smoking in rectal tissue. However,
while we cannot identify the exact functionality these miRNAs
have, we are able to see that these miRNAs have been associated
with CRC prognosis, and this supports the assertion that smoking
can have a functional impact in rectal cancer, possibly through
regulation of miRNA expression. Our rectal cancer sample size was
not large enough to have sufﬁcient power to detect signiﬁcant
associations between smoking and CIMP/MSI tumor phenotype
given the rare nature of MSI rectal tumors. We encourage others to
replicate this analysis with larger samples.
L.E. Mullany et al. / Cancer Epidemiology 45 (2016) 98–107 1075. Conclusions
Overall, our ﬁndings suggest that smoking is able to alter
miRNA expression in rectal carcinoma tissue, and they lend
support to the hypothesis that this alteration is responsible for
worsening survival for rectal cancer cases and may inﬂuence CIMP
and MSI tumor phenotype.
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